Loading...
01/09 23:03
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights several negative aspects: trading suspension and delisting from NYSE, no revenue due to the sale of Vyleesi, and a significant cash position decrease. Although operating expenses and net loss decreased, concerns about financial viability and market perception persist. The Q&A section provided limited positive insights, with management's unclear responses adding to uncertainties. The absence of shareholder return plans further contributes to a negative outlook. Given these factors, a negative stock price movement is expected.
Revenue $0 million (no product sales), year-over-year change: N/A due to the sale of Vyleesi’s rights in December 2023.
Operating Expenses $4.8 million, year-over-year change: decreased from $9.2 million, due to lower spending related to MCR programs.
Net Cash Used in Operations $5.4 million, year-over-year change: decreased from $8.6 million, due to a decrease in net loss and working capital changes.
Net Loss $4.8 million, year-over-year change: decreased from $8.4 million, primarily driven by decreased operating expenses.
Cash and Cash Equivalents $2.5 million as of March 31, 2025, compared to $9.5 million at June 30, 2024, indicating a decrease in cash position.
Sale of Vyleesi's Rights: Palatin completed the sale of Vyleesi’s worldwide rights for female sexual dysfunction to Cosette Pharmaceuticals for up to $171 million in December 2023.
Stock Trading Status: Palatin's common stock was suspended from trading on the NYSE American and began trading on the OTC Pink market on May 8, 2025.
Operating Expenses: Total operating expenses were $4.8 million for the quarter ended March 31, 2025, down from $9.2 million for the same quarter last year.
Net Cash Used in Operations: Net cash used in operations was $5.4 million for the quarter ended March 31, 2025, compared to $8.6 million for the same period in 2024.
Response to Delisting: Palatin is assessing all available options in response to the NYSE's decision to delist its common stock.
Stock Trading Suspension and Delisting Risk: Palatin's common stock was suspended from trading on the NYSE American due to a low selling price, leading to potential delisting.
Financial Viability Risk: The company reported a significant decrease in cash and cash equivalents, from $9.5 million to $2.5 million, raising concerns about financial stability.
Revenue Generation Risk: Palatin did not record any product sales for the quarter due to the sale of Vyleesi's rights, impacting revenue generation.
Operational Expense Management Risk: Operating expenses decreased but remain a concern, with total operating expenses reported at $4.8 million.
Market Position Risk: The transition to the OTC Pink market may affect investor confidence and market perception of the company.
Stock Trading Status: Palatin's common stock was suspended from trading on the NYSE American and began trading on the OTC Pink market due to low selling price.
Delisting Review: Palatin is assessing all available options regarding the NYSE's decision to delist its common stock.
Vyleesi Sale: Palatin completed the sale of Vyleesi’s worldwide rights for female sexual dysfunction to Cosette Pharmaceuticals for up to $171 million.
Operating Expenses: Total operating expenses for Q3 2025 were $4.8 million, a decrease from $9.2 million in Q3 2024.
Net Cash Used in Operations: Net cash used in operations for Q3 2025 was $5.4 million, down from $8.6 million in Q3 2024.
Net Loss: Net loss for Q3 2025 was $4.8 million, compared to $8.4 million in Q3 2024.
Cash Position: As of March 31, 2025, cash and cash equivalents were $2.5 million, down from $9.5 million at June 30, 2024.
Shareholder Return Plan: Palatin Technologies did not discuss any share buyback program or dividend program during the earnings call.
The earnings call highlights strong financial performance with increased revenue and net income due to the BI agreement. Operating expenses decreased, improving cash flow. The Q&A revealed confidence in product differentiation and market potential despite competitive risks. The BI milestone payment and recent public offering enhance financial health. Overall, the financial and strategic outlook is positive, with potential for further growth from pipeline developments.
The earnings call highlights several negative aspects: trading suspension and delisting from NYSE, no revenue due to the sale of Vyleesi, and a significant cash position decrease. Although operating expenses and net loss decreased, concerns about financial viability and market perception persist. The Q&A section provided limited positive insights, with management's unclear responses adding to uncertainties. The absence of shareholder return plans further contributes to a negative outlook. Given these factors, a negative stock price movement is expected.
The earnings call summary indicates significant challenges: liquidity concerns with cash dropping from $9.5M to $2.4M, no product sales in Q1 2025, and increased net loss. Despite a deferred payment and potential partnerships, the focus on MCR-4 obesity limits diversification and increases risk. Q&A insights reveal interest but lack concrete partnership details, adding uncertainty. Overall, the negative financials and strategic risks outweigh the potential positives, leading to a negative sentiment prediction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
